Long-term evolocumab therapy leads to further reductions in cardiovascular events

Retrieved on: 2022-08-29 07:23:47

Tags for this article:

Click the tags to see associated articles and topics

Long-term evolocumab therapy leads to further reductions in cardiovascular events. View article details on hiswai:

Excerpt

Barcelona, Spain – 29 Aug 2022: Long-term low-density lipoprotein (LDL) ... getting prolonged treatment with the PCSK9 inhibitor evolocumab.”.

Article found on: www.escardio.org